GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Acelyrin Inc (NAS:SLRN) » Definitions » ROC (Joel Greenblatt) %

Acelyrin (Acelyrin) ROC (Joel Greenblatt) % : -9,880.51% (As of Mar. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Acelyrin ROC (Joel Greenblatt) %?

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Acelyrin's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was -9,880.51%.

The historical rank and industry rank for Acelyrin's ROC (Joel Greenblatt) % or its related term are showing as below:

SLRN' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -12509.31   Med: -12509.31   Max: -10907.67
Current: -10907.67

During the past 3 years, Acelyrin's highest ROC (Joel Greenblatt) % was -10907.67%. The lowest was -12509.31%. And the median was -12509.31%.

SLRN's ROC (Joel Greenblatt) % is ranked worse than
94.07% of 1467 companies
in the Biotechnology industry
Industry Median: -334.45 vs SLRN: -10907.67

Acelyrin's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was 0.00% per year.


Acelyrin ROC (Joel Greenblatt) % Historical Data

The historical data trend for Acelyrin's ROC (Joel Greenblatt) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Acelyrin ROC (Joel Greenblatt) % Chart

Acelyrin Annual Data
Trend Dec21 Dec22 Dec23
ROC (Joel Greenblatt) %
- - -12,509.31

Acelyrin Quarterly Data
Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
ROC (Joel Greenblatt) % Get a 7-Day Free Trial Premium Member Only Premium Member Only -45,817.32 -7,076.20 -11,400.30 -12,470.65 -9,880.51

Competitive Comparison of Acelyrin's ROC (Joel Greenblatt) %

For the Biotechnology subindustry, Acelyrin's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Acelyrin's ROC (Joel Greenblatt) % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Acelyrin's ROC (Joel Greenblatt) % distribution charts can be found below:

* The bar in red indicates where Acelyrin's ROC (Joel Greenblatt) % falls into.



Acelyrin ROC (Joel Greenblatt) % Calculation

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:

ROC (Joel Greenblatt) %=EBIT/Average of (Net fixed Assets + Net Working Capital)

EBIT stands for Earnings Before Interest and Taxes.

Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.

GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.

Working Capital(Q: Dec. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 10.563) - (78.772 + 0 + 6.387)
=-74.596

Working Capital(Q: Mar. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 10.088) - (49.062 + 0 + 3.221)
=-42.195

When net working capital is negative, 0 is used.

So ROC (Joel Greenblatt) % of Acelyrin for the quarter that ended in Mar. 2024 can be restated as:

ROC (Joel Greenblatt) %(Q: Mar. 2024 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2023  Q: Mar. 2024
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-331.096/( ( (3.374 + max(-74.596, 0)) + (3.328 + max(-42.195, 0)) )/ 2 )
=-331.096/( ( 3.374 + 3.328 )/ 2 )
=-331.096/3.351
=-9,880.51 %

Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Acelyrin  (NAS:SLRN) ROC (Joel Greenblatt) % Explanation

The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.

Joel Greenblatt uses his definition of Return on Capital and Earnings Yield (Joel Greenblatt) % to rank companies.


Acelyrin ROC (Joel Greenblatt) % Related Terms

Thank you for viewing the detailed overview of Acelyrin's ROC (Joel Greenblatt) % provided by GuruFocus.com. Please click on the following links to see related term pages.


Acelyrin (Acelyrin) Business Description

Traded in Other Exchanges
N/A
Address
4149 Liberty Canyon Road, Agoura Hills, CA, USA, 91301
Acelyrin Inc is a late-stage clinical biopharmaceutical company. It is focused on providing patients life-changing new treatment options by identifying, acquiring, and accelerating development and commercialization of promising drug candidates.
Executives
Shao-lee Lin director, officer: Chief Executive Officer C/O ACELYRIN, INC., 4149 LIBERTY CANYON RD., AGOURA HILLS CA 91301
Gil M Labrucherie officer: Interim CFO 150 INDUSTRIAL ROAD, SAN CARLOS CA 94070
Beth C Seidenberg director, 10 percent owner
Henry O Gosebruch director 1 N. WAUKEGAN ROAD, NORTH CHICAGO IL 60064-6092
Mardi Dier officer: CFO and CBO C/O ACELYRIN, INC., 4149 LIBERTY CANYON RD., AGOURA HILLS CA 91301
Mina Kim officer: Chief Legal & Admin. Officer C/O ACELYRIN, INC., 4149 LIBERTY CANYON RD., AGOURA HILLS CA 91301
Ronald Oyston officer: Chief People Officer C/O ACELYRIN, INC., 4149 LIBERTY CANYON ROAD, AGOURA HILLS CA 91301
Paul Peloso officer: Chief Medical Officer C/O ACELYRIN, INC., 4149 LIBERTY CANYON ROAD, AGOURA HILLS CA 91301
Dawn Svoronos director C/O MEDIVATION, INC., 525 MARKET ST., 36TH FLOOR, SAN FRANCISCO CA 94105
Daniel J. Becker director C/O NEW LEAF VENTURE PARTNERS, TIMES SQ TOWER, 7 TIMES SQ, STE 3502, NEW YORK NY 10036
Westlake Biopartners Fund Ii, L.p. 10 percent owner 3075 TOWNSGATE ROAD, SUITE 140, WESTLAKE VILLAGE CA 91361
Ayurmaya Capital Management Company, Lp director, 10 percent owner, other: See Remarks 1000 WINTER STREET, SUITE 4500, WALTHAM MA 02451
Sean E Harper 10 percent owner AMGEN INC., ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA 91320-1799
Melanie Gloria officer: Chief Operating Officer C/O ACELYRIN, INC., 4149 LIBERTY CANYON ROAD, AGOURA HILLS CA 91301
Westlake Biopartners Gp Ii, Llc 10 percent owner 3075 TOWNSGATE ROAD, SUITE 140, WESTLAKE VILLAGE CA 91361

Acelyrin (Acelyrin) Headlines